US equities
|
NVDA
$240.06
▲+0.49%
SPCX
$172.85
▲+1.03%
MU
$1,065.57
▲+0.15%
MRVL
$289.92
▲+6.88%
AMD
$654.72
▲+3.64%
INTC
$114.77
▼-1.22%
AVGO
$380.02
▲+4.83%
TSLA
$380.38
▲+0.44%
NVDA
$240.06
▲+0.49%
SPCX
$172.85
▲+1.03%
MU
$1,065.57
▲+0.15%
MRVL
$289.92
▲+6.88%
AMD
$654.72
▲+3.64%
INTC
$114.77
▼-1.22%
AVGO
$380.02
▲+4.83%
TSLA
$380.38
▲+0.44%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Plandai Biotechnology Inc
(OP:
PLPL
)
0.0001
UNCHANGED
Last Price
Updated: 9:30 AM EDT, Sep 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Plandai Biotechnology Inc
Plandai Biotechnology, Inc. Announces Rescission of Material Definitive Agreement with Good Salt, LLC
August 01, 2023
Via
ACCESSWIRE
Third-Party Valuation Firm Provides Estimated Valuation of ByoPlanet's (A Subsidiary Of Plandai – $PLPL) Business and Assets
May 31, 2023
Via
ACCESSWIRE
Byoplanet Unveils Bold Roadmap for the Upcoming Year, Under the Leadership of CEO Rick O'Shea
May 31, 2023
Via
ACCESSWIRE
ByoPlanet's bCOOL(TM) Cooling Technology Enhances Performance and Recovery for Major League and College Teams
May 25, 2023
Via
ACCESSWIRE
ByoPlanet and Merck Animal Health Announce Partnership with USEF
May 23, 2023
Via
ACCESSWIRE
Plandai Subsidiary ByoPlanet Announces Strategic Distribution Agreement with Merck Animal Health
May 19, 2023
Via
ACCESSWIRE
Following Completed Share Exchange Agreement with ByoPlanet, Plandai Announces Material Rebranding to Disinfectant Industry Focus
May 18, 2023
Via
ACCESSWIRE
ByoPlanet Announces Completion of Share Exchange Agreement with Plandai Biotechnology
May 17, 2023
Via
ACCESSWIRE
Plandai Biotechnology, Inc. Announces Entry into Material Share Exchange Agreement with Good Salt, LLC
March 20, 2023
Via
ACCESSWIRE
Plandai Biotechnologies, Inc. Announces Termination of Asset Acquisition Agreement with EV Hotel, Updates on Status of Independent Audit
January 04, 2023
Via
ACCESSWIRE
EV Hotel Corp. and Plandai Biotechnologies Enter Into Asset Acquisition Agreement to Create the Leading Smart Hotel Brand - EV Hotel Corp.
November 08, 2022
Via
ACCESSWIRE
Plandai Biotechnologies, Inc. Announces Entry into Non-Binding Letter of Intent, Updates on Status of Independent Audit
October 06, 2022
Via
ACCESSWIRE
Plandai Biotechnology, Inc. Announces Termination of Non-Binding Letter of Intent
July 27, 2022
Via
ACCESSWIRE
Plandai Biotechnology, Inc. Announces Termination of Non-Binding Letter of Intent
July 27, 2022
SAN DIEGO, CA / ACCESSWIRE / July 27, 2022 / Plandai Biotechnology, Inc. ("Plandai" or the "Company") announces the termination of its non-binding letter of intent dated May 23, 2022, with Ms. Jessie...
From
Plandai Biotechnology
Via
AccessWire
SEC Cancels Regulatory Penalty and Interest Concerning Legacy Civil Enforcement Action
June 22, 2022
SAN DIEGO, CA / ACCESSWIRE / June 22, 2022 / Plandai Biotechnology Inc. (OTC PINK:PLPL) (the "Company") today announced that the U.S. Securities and Exchange Commission canceled civil penalties and...
From
Plandai Biotechnology
Via
AccessWire
Topics
Regulatory Compliance
Plandai Biotechnology In Non-Binding Letter of Intent to Acquire Rights to Puriblood’s Leukocyte Reduction Blood Filtration System with Plans to Address the International Blood Filtration Market
May 23, 2022
SAN DIEGO, CA / ACCESSWIRE / May 23, 2022 / Plandai Biotechnology Inc. (OTC PINK:PLPL) (the "Company") today announced its entry into a non-binding letter of intent to enter into a new business through...
From
Plandai Biotechnology
Via
AccessWire
